Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

39 trials with published results (18%)

Research Maturity

81 completed trials (38% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

5.6%

12 terminated out of 215 trials

Success Rate

87.1%

+0.6% vs benchmark

Late-Stage Pipeline

16%

34 trials in Phase 3/4

Results Transparency

48%

39 of 81 completed with results

Key Signals

39 with results87% success12 terminated

Data Visualizations

Phase Distribution

190Total
Not Applicable (94)
Early P 1 (1)
P 1 (15)
P 2 (46)
P 3 (19)
P 4 (15)

Trial Status

Completed81
Recruiting44
Unknown29
Active Not Recruiting21
Withdrawn13
Not Yet Recruiting12

Trial Success Rate

87.1%

Benchmark: 86.5%

Based on 81 completed trials

Clinical Trials (215)

Showing 20 of 20 trials
NCT06462196Recruiting

Natural History of Depression, Bipolar Disorder and Suicide Risk

NCT06518720Phase 2RecruitingPrimary

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

NCT06512220Phase 2RecruitingPrimary

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

NCT05144789Not ApplicableCompletedPrimary

Personalized Therapeutic Neuromodulation for Anhedonic Depression

NCT03680781Not ApplicableCompletedPrimary

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

NCT07706478RecruitingPrimary

Working Mechanisms and Effectiveness of IV Ketamine-assisted Psychotherapy on Depression in TRD Clients

NCT03952962Not ApplicableRecruitingPrimary

Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression

NCT06480201Phase 1Recruiting

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

NCT05660642Phase 2RecruitingPrimary

An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression

NCT03573349Early Phase 1Active Not Recruiting

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

NCT05849402Not ApplicableActive Not Recruiting

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

NCT05774665Phase 2Active Not RecruitingPrimary

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

NCT06423430Not ApplicableRecruitingPrimary

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

NCT07227103Phase 2Not Yet RecruitingPrimary

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT04106466Not ApplicableActive Not Recruiting

DBS for TRD With the Medtronic Summit RC+S

NCT06085950Not ApplicableRecruitingPrimary

Transcranial Ultrasonic Stimulation in Treatment-resistant Depression : an Open-label Pilot Trial

NCT05773755Not ApplicableRecruiting

DBS for TRD With the Medtronic Percept PC

NCT03887715Not ApplicableRecruitingPrimary

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

NCT06096207Phase 1RecruitingPrimary

DBS for Depression

NCT05913401Not ApplicableCompletedPrimary

Exercise to Augment TMS in Those With Treatment Resistant Depression

Scroll to load more

Research Network

Activity Timeline